NAD+ is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C11H15N2O8P | Identifies the atoms in the nucleotide |
| Molar mass | 334.22 g/mol | Calculated from the molecular formula |
| Appearance | White to off-white powder | Typical for purified solid material |
| Solubility | Water-soluble | Polar nucleotide; less soluble in nonpolar solvents |
| Common synonyms | Nicotinamide mononucleotide; beta-NMN | beta-NMN refers to the common anomeric form |
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. The compound exists in cells as an intermediate in the production of nicotinamide adenine dinucleotide, a central redox cofactor. NMN is distinct from nicotinamide riboside, another related pyridine nucleotide, although the two compounds can converge in metabolic pathways. Its chemical formula is C11H15N2O8P, and it carries a net negative charge at physiological pH.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Superconductivity in the cuprates is considered unconventional and is not explained by BCS theory. Possible pairing mechanisms for cuprate superconductivity continue to be the subject of considerable debate and further research. Similarities between the low-temperature antiferromagnetic state in undoped materials and the low-temperature superconducting state that emerges upon doping, primarily the dx2−y2 orbital state of the Cu2+ ions, suggest that electron-phonon coupling is less relevant in cuprates. Recent work on the Fermi surface has shown that nesting occurs at four points in the antiferromagnetic Brillouin zone where spin waves exist and that the superconducting energy gap is larger at these points. The weak isotope effects observed for most cuprates contrast with conventional superconductors that are well described by BCS theory. In 1987, Philip Anderson proposed that superexchange could act as a high-temperature superconductor pairing mechanism. In 2016, Chinese physicists found a correlation between a cuprate's critical temperature and the size of the charge transfer gap in that cuprate, providing support for the superexchange hypothesis. A 2022 study found that the varying density of actual Cooper pairs in a bismuth strontium calcium copper oxide superconductor matched with numerical predictions based on superexchange. But so far there is no consensus on the mechanism, and the search for an explanation continues. Similarities and differences in the properties of hole-doped and electron-doped cuprates:
In September 2022, Newsom signed Senate Bill 107 into law, making California the first sanctuary state for transgender youth. He issued an official state proclamation for Pride Month in June 2023, issued a fine of $1.5 million to a school district whose board rejected a curriculum including a biography of gay rights leader Harvey Milk, and signed a bill prohibiting schools from banning textbooks based on their inclusion of references to people from minority groups or the LGBT community. In July 2024, he signed the "SAFETY Act", which prohibits schools from outing students' gender identity to their parents without the students' consent. Newsom later vetoed several bills that the Assembly had passed by a wide margin, one of which would have instructed judges who preside over custody battles to take into account parents' affirmation of their children's gender identity, and one of which would have mandated that insurance plans serving California residents cover the cost of gender-affirming care. This, and later comments by Newsom on his podcast calling trans women's participation in women's sports "deeply unfair", appeared to signify a change in course in which he forsook his support of key transgender issues to appeal to right-wing audiences. He received backlash from some progressive commentators and the disapproval and condemnation of several of his fellow Democrats, such as California State Assemblyman Chris Ward and California State Senator Caroline Menjivar of the LGBTQ+ Caucus, who said his comments "profoundly sickened and frustrated" them.
== Further reading == Angeli S, Ceron F, Scaloni A, Monti M, Monteforti G, Minnocci A, et al. (1999). "Purification, structural characterization, cloning and immunocytochemical localization of chemoreception proteins from Schistocerca gregaria". Eur J Biochem. 262 (3): 745–54. doi:10.1046/j.1432-1327.1999.00438.x. PMID 10411636.
== Further reading == Hoffman, D.C., Ghiorso, A., Seaborg, G. T. The transuranium people: the inside story, (2000), 201–229 Morss, L. R., Edelstein, N. M., Fuger, J., The chemistry of the actinide and transactinide element, 3, (2006), 1630–1636 A Guide to the Elements – Revised Edition, Albert Stwertka, (Oxford University Press; 1998) ISBN 0-19-508083-1
Sources: en.wikipedia.org
=== Functional Genomics === This program studies genes involved in physiological systems and their pharmaceutical applications. It characterizes gene functions and interactions using rodent models at the Czech Centre for Phenogenomics, which is part of the Infrafrontier consortium. Research includes liver function, cardiovascular dysfunction, diabetes, metabolic disorders, hearing loss, and ocular disease.
Rainwater will also be harvested at prospective locations along the expressway to ensure water availability. The expressway will connect several tourism circuits offering eco, pilgrim, and heritage tourism, which will include wildlife resorts, tiger safaris, museums, sightseeing destinations, and theme-based retail outlets. The expressway is a 6 lane (with paved and unpaved shoulders on both sides) access-controlled super communication expressway comprising a total width of 120 m (90 m in hilly terrain) with a central median of 22.5 m. The expressway will be the country's largest 'Greenfield' route alignment, including 65 flyovers/viaducts, 24 interchanges, 6 tunnels, 400+ vehicular, 300+ pedestrian underpasses, and cattle underpasses at strategic locations.
== Chimerism and intersex == The concept of a "human hermaphrodite" resulting from chimerism is largely a misconception. Most intersex individuals are not chimeras, and most human chimeras are not observed to have intersex traits. Theoretically, if a gynandromorphic human chimera were to have fully functioning male and female gonad tissue, such an individual could self-fertilize; this hypothesis is backed by the fact that hermaphroditic animal species commonly reproduce in this way, and it has been observed in a rabbit. However, no such case of functional self-fertilization has ever been documented in humans; and it is non-existent or extremely rare in mammals, especially in humans. While humans are known to have sex characteristics that diverge from typical males or typical females, these individuals fall under the social umbrella of intersex conditions and traits, and some consider the term "hermaphrodite" to be a slur when applied to them.
=== Antibacterial activity === Certain antimicrobial biomolecules found in the spider silk of P. phalangioides are able to elicit an inhibitory effect on drug-resistant human pathogens including gram-positive bacteria L. monocytogenes, gram-negative E. coli, Staphylococcus aureus, Bacillus subtilis, and Pseudomonas aeruginosa. More generally, researchers are hoping that the anti-microbial biomolecules of this spider silk could serve as a natural anti-microbial agent in the future against a host of infectious bacterial diseases that are resistant to antibiotics.
=== Biological role === Nicotinamide occurs as a component of a variety of biological systems, including within the vitamin B family and specifically the vitamin B3 complex. It is also a critically important part of the structures of NADH and NAD+, where the N-substituted aromatic ring in the oxidised NAD+ form undergoes reduction with hydride attack to form NADH. The NADPH/NADP+ structures have the same ring, and are involved in similar biochemical reactions. Nicotinamide can be methylated in the liver to biologically inactive 1-methylnicotinamide when there are sufficient methyl donors.
Sources: en.wikipedia.org
The research, as cited by the cover story of the November 2005 issue of National Geographic, asserts that Adventists live longer because they do not smoke or drink alcohol, have a day of rest every week, and maintain a healthy, low-fat vegetarian diet that is rich in nuts and beans. The cohesiveness of Adventists' social networks has also been put forward as an explanation for their extended lifespan. Since Dan Buettner's 2005 National Geographic story about Adventist longevity, his book, The Blue Zones: Lessons for Living Longer From the People Who've Lived the Longest, named Loma Linda, California, a "blue zone" because of the large concentration of Seventh-day Adventists. He cites the Adventist emphasis on health, diet, and Sabbath-keeping as primary factors for Adventist longevity. An estimated 35% of Adventists practice vegetarianism or veganism, according to a 2002 worldwide survey of local church leaders. North American Adventist health study recruitments from 2001 to 2007 found a similar prevalence of vegetarianism/veganism. A small majority of Adventists, 54%, were conventional meat-eaters. Of the remaining 46% it was found that 28% were Ovo/Lacto-vegetarians, 10% were Pesco-vegetarians and 8% were vegans. It is common for Adventists who choose to eat meat to also eat plant-based foods; 6% of the "meat-eaters" group restricted their intake of meat/fish to no more than once per week.
==== 2020s ==== On October 28, 2020, Panera announced they would add pizza to their menu to increase dinner options for customers. Panera announced on August 25, 2021, that it had merged with Caribou Coffee and Einstein Bros. Bagels to form Panera Brands. In August 2022, the company announced that it was testing the use of artificial intelligence in its drive-thru lanes via two locations in upstate New York. It used OpenCity's voice ordering technology, Tori. At the time of the announcement, roughly 45% of the chain's locations had drive-thru lanes. In making this move, the firm was joining other firms in the restaurant industry, like McDonald's, Burger King, and Taco Bell, and it came on top of other uses of artificial intelligence at the chain. In September 2022, Panera announced that legacy St. Louis Bread Co. locations outside St. Louis City and St. Louis County would be rebranded as Panera when remodeled, with locations in the inner core of the metro retaining the Bread Co. name. One location in St. Louis County is named Panera as it is a prototype of the "Next Gen" restaurant design. In mid-2023, Panera moved its headquarters from Sunset Hills to Fenton, Missouri, downsizing the square footage by more than half. The move preceded two rounds of corporate layoffs in late 2023 and 2024. In December 2023, it was learned that Panera Bread confidentially filed to go public again. The company was last publicly traded in 2017 before being acquired by JAB Holding for $7.5 billion.
Tendinous area displaying longitudinally oriented fibroblasts and a parallel arrangement of collagen fibres Fibrocartilaginous region of variable thickness where the structure of the cells changes to chondrocytes Abrupt transition from cartilaginous to calcified fibrocartilage—often called 'tidemark' or 'blue line' Bone
=== Not marketed === ACT-335827 – selective OX1 antagonist Almorexant (ACT-078573) – dual OX1 and OX2 antagonist – half-life 13–19 hours – development of the drug was abandoned in January 2011 EMPA – selective OX2 antagonist Filorexant (MK-6096) – dual OX1 and OX2 antagonist – half-life 3–6 hours – development was discontinued in 2015 GSK-649868 (SB-649868) – dual OX1 and OX2 antagonist – was in development for potential use in sleep disorders JNJ-10397049 – selective OX2 antagonist RTIOX-276 – selective OX1 antagonist SB-334867 – first non-peptide selective OX1 antagonist – has been shown to produce sedative and anorectic effects in animals SB-408124 – selective OX1 antagonist TCS-OX2-29 – first non-peptide selective OX2 antagonist
A 2004 meta-analysis of randomised controlled clinical trials that compared benzodiazepines to zopiclone or other Z drugs such as zolpidem and zaleplon has found few clear and consistent differences between zopiclone and the benzodiazepines in sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events, tolerance, rebound insomnia, and daytime alertness.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.
NMN is a direct precursor to NAD+ in the salvage pathway. The enzyme NMNAT converts NMN into NAD+ by adding an adenine nucleotide group. This relationship is why NMN is studied in the context of NAD+ decline.
Yes, NMN is produced naturally in cells as part of NAD+ recycling. It also appears in small and variable amounts in some foods. Its natural presence does not by itself establish that supplemental NMN has clinical benefits.
NMN is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis. It consists of nicotinamide attached to a ribose phosphate unit. Cells produce it through the salvage pathway.